Autoantibody spark response predicts treatment outcome in patients receiving chemoradiation followed by durvalumab therapy

Autoantibody spark response predicts treatment outcome in patients receiving chemoradiation followed by durvalumab therapy

Abstract The PACIFIC regimen, comprising chemoradiotherapy (CRT) followed by maintenance with the immune checkpoint inhibitor (ICI) durvalumab, has become the standard of care for patients with unresectable non-small cell lung cancer (NSCLC). Although ICI is used to prevent recurrence by targeting r...

Full description

Saved in:
Bibliographic Details
Main Authors: Takeru Mori, Mio Kitagawa, Tomokazu Hasegawa, Masanori Someya, Takaaki Tsuchiya, Toshio Gocho, Tomoko Honjo, Mirei Date, Mariko Morii, Ai Miyamoto, Junichiro Futami
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Autoantibodies
PACIFIC regimen
ICIs
Immune monitoring
Online Access:https://doi.org/10.1038/s41598-025-12069-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-12069-5

Similar Items